Michael Schwake1, Stephanie Schipmann2, Michael Müther2, Michaela Köchling2, Angela Brentrup2, Walter Stummer2. 1. Department of Neurosurgery, University Hospital Münster, Germany Albert-Schweitzer-Campus 1, Building A1, 48149, Munster, Germany. schwakem@uni-muenster.de. 2. Department of Neurosurgery, University Hospital Münster, Germany Albert-Schweitzer-Campus 1, Building A1, 48149, Munster, Germany.
Abstract
BACKGROUND: 5-Aminolevulinic acid (5-ALA)-guided resection of gliomas in adults enables better differentiation between tumor and normal brain tissue, allowing a higher degree of resection, and improves patient outcomes. In recent years, several reports have emerged regarding the use of 5-ALA in other brain tumor entities, including pediatric brains tumors. Since gross total resection (GTR) of many brain tumors in children is crucial and the role of 5-ALA-guided resection of these tumors is not clear, we sought to perform a comprehensive literature review on this topic. METHODS: A systematic literature review of EMBASE and MEDLINE/PubMed databases revealed 19 eligible publications encompassing 175 5-ALA-guided operations on pediatric brain tumors. To prevent bias, publications were revised independently by two authors. RESULTS: We found that 5-ALA-guided resection enabled the surgeons to identify the tumor more easily and was considered helpful mainly in cases of glioblastoma (GBM, 21/27, 78%), anaplastic ependymoma WHO grade III (10/14, 71%), and anaplastic astrocytoma (4/6, 67%). In contrast, cases of pilocytic astrocytomas (PAs) and medulloblastomas 5-ALA-guided surgery did not show consistent fluorescent signals and 5-ALA was considered helpful only in 12% and 22% of cases, respectively. Accumulation of fluorescent porphyrins seems to depend on WHO tumor grading. One important finding is that when 5-ALA-guided resections were considered helpful, the degree of resection was higher than is cases where it was not helpful. The rate of adverse events related to 5-ALA was negligible, especially new postoperative sequelae. CONCLUSION: 5-ALA could play a role in resection of pediatric brain tumors. However, further prospective clinical trials are needed.
BACKGROUND:5-Aminolevulinic acid (5-ALA)-guided resection of gliomas in adults enables better differentiation between tumor and normal brain tissue, allowing a higher degree of resection, and improves patient outcomes. In recent years, several reports have emerged regarding the use of 5-ALA in other brain tumor entities, including pediatric brains tumors. Since gross total resection (GTR) of many brain tumors in children is crucial and the role of 5-ALA-guided resection of these tumors is not clear, we sought to perform a comprehensive literature review on this topic. METHODS: A systematic literature review of EMBASE and MEDLINE/PubMed databases revealed 19 eligible publications encompassing 175 5-ALA-guided operations on pediatric brain tumors. To prevent bias, publications were revised independently by two authors. RESULTS: We found that 5-ALA-guided resection enabled the surgeons to identify the tumor more easily and was considered helpful mainly in cases of glioblastoma (GBM, 21/27, 78%), anaplastic ependymoma WHO grade III (10/14, 71%), and anaplastic astrocytoma (4/6, 67%). In contrast, cases of pilocytic astrocytomas (PAs) and medulloblastomas5-ALA-guided surgery did not show consistent fluorescent signals and 5-ALA was considered helpful only in 12% and 22% of cases, respectively. Accumulation of fluorescent porphyrins seems to depend on WHO tumor grading. One important finding is that when 5-ALA-guided resections were considered helpful, the degree of resection was higher than is cases where it was not helpful. The rate of adverse events related to 5-ALA was negligible, especially new postoperative sequelae. CONCLUSION:5-ALA could play a role in resection of pediatric brain tumors. However, further prospective clinical trials are needed.
Authors: Jacopo Falco; Julius Höhne; Morgan Broggi; Emanuele Rubiu; Francesco Restelli; Ignazio G Vetrano; Marco Schiariti; Elio Mazzapicchi; Giulio Bonomo; Paolo Ferroli; Karl-Michael Schebesch; Francesco Acerbi Journal: Front Oncol Date: 2022-08-09 Impact factor: 5.738
Authors: Elizaveta I Kozlikina; Igor S Trifonov; Mikhail V Sinkin; Vladimir V Krylov; Victor B Loschenov Journal: Bioengineering (Basel) Date: 2022-03-03
Authors: Shachar Kenan; Haixiang Liang; Howard J Goodman; Andrew J Jacobs; Amanda Chan; Daniel A Grande; Adam S Levin Journal: J Orthop Surg Res Date: 2020-03-05 Impact factor: 2.359
Authors: Lianne M Wellens; Marion M Deken; Cornelis F M Sier; Hannah R Johnson; Fàtima de la Jara Ortiz; Shadhvi S Bhairosingh; Ruben D Houvast; Waleed M Kholosy; Victor M Baart; Annique M M J Pieters; Ronald R de Krijger; Jan J Molenaar; Ellen J Wehrens; Johanna F Dekkers; Marc H W A Wijnen; Alexander L Vahrmeijer; Anne C Rios Journal: Sci Rep Date: 2020-10-19 Impact factor: 4.379
Authors: Raquel Leon; Himar Fabelo; Samuel Ortega; Juan F Piñeiro; Adam Szolna; Maria Hernandez; Carlos Espino; Aruma J O'Shanahan; David Carrera; Sara Bisshopp; Coralia Sosa; Mariano Marquez; Jesus Morera; Bernardino Clavo; Gustavo M Callico Journal: Sci Rep Date: 2021-10-04 Impact factor: 4.379